TOP TEN perturbations for 38673_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38673_s_at
Selected probe(set): 213348_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38673_s_at (213348_at) across 6674 perturbations tested by GENEVESTIGATOR:

hepatocyte (ESC) / Hep-G2

Relative Expression (log2-ratio):8.087827
Number of Samples:8 / 9
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):8.016643
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):5.342965
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.

small cell lung cancer study 4 (1. gen. PDX) / small cell lung cancer study 4 (XCL from PDX)

Relative Expression (log2-ratio):5.172452
Number of Samples:4 / 3
Experimental small cell lung cancer study 4 (1. gen. PDX)
A small cell lung cancer (SCLC) primary xenograft tumor tissue samples derived from three chemo-naive patients (LX22; LX33 and LX36; first generation-1. gen.). The discarded tissue obtained during bronchoscopy of SCLC patients was used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice (NOD/SCID). The mice were sacrificed when the P0 tumors reached 1cm in diameter.
Control small cell lung cancer study 4 (XCL from PDX)
Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) patient derived xenografts (PDX). The discarded tissue from three chemo-naive patients (LX22; LX33 and LX35) was obtained during bronchoscopy and used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice. The mice were sacrificed when the P0 tumors reached 1cm in diameter. Obtained cells were used for conventional cell culture cultivation.

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-5.048111
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

pancreatic islet study 3 (expanded; PPRF) / normal pancreatic islet sample

Relative Expression (log2-ratio):-4.9511347
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (expanded; PPRF)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded according to Pharmaceutical Production Research Facility Protocol (PPRF) for 6 weeks. Expansion phase: Approximately 2,500 islet equivalents were seeded onto 75-cm2 fibronectin-coated tissue culture-treated flasks in a proprietary serum-free medium (PPRF medium). The serum-free PPRF medium was supplemented with 30% serum-free mesenchymal-conditioned medium. When the cell migration resulted in the formation of large-size colonies, the cells were harvested by trypsinization and replated into new tissue culture flasks. Once the cells reached near confluence (80–90%) in monolayer, they were trypsinized, counted, and subcultured at a density of 5,000 cells per cm2. Thereafter, cells were serially passaged using the same protocol.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

rheumatoid arthritis study 37 (mono; CD14+ CD16+) / rheumatoid arthritis study 37 (mono; CD14+ CD16-)

Relative Expression (log2-ratio):4.7801447
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 37 (mono; CD14+ CD16+)
Peripheral blood CD14+ CD16+ monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm
Control rheumatoid arthritis study 37 (mono; CD14+ CD16-)
Peripheral blood CD14+ CD16- monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)

Relative Expression (log2-ratio):4.758068
Number of Samples:2 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

HCC study 20 (CDX; Hep-G2; orthotopic) / HCC study 20 (PDX; orthotopic)

Relative Expression (log2-ratio):4.7345123
Number of Samples:5 / 11
Experimental HCC study 20 (CDX; Hep-G2; orthotopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; orthotopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks.

esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)

Relative Expression (log2-ratio):4.7207804
Number of Samples:2 / 3
Experimental esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).